

← [Back to overview](#)

Ad hoc announcement pursuant to Art. 53 Listing Rules
Media Release – Jun 12, 2024

Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering

- Siegfried to acquire a CDMO specialized in early-phase development and manufacturing services in Grafton, Wisconsin (US)
- The new site is set to strengthen Siegfried's customer offering for Drug Substances in terms of capabilities and geography
- Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services, to generate attractive growth opportunities

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin (US).

The new site, which specializes in early-phase development and manufacturing services with an experienced team of more than 80 employees, is set to strengthen Siegfried's customer offering for Drug Substances in terms of capabilities and geographical coverage. Siegfried intends to develop the site into a best-in-class hub for early-phase CDMO services for its global customer base, including services for projects with highly potent APIs. Subject to customary closing conditions, the transaction is expected to close by July 1, 2024.

Reto Suter, CEO ad interim and CFO of Siegfried, commented: "With this acquisition, we enhance our offering with early-stage development services for Drug Substances and become even more relevant and attractive to our customers. Siegfried now offers an integrated range of services from early-stage development to commercial production of APIs through to the manufacturing of fully formulated Drug Products. This transaction will generate attractive opportunities and will further accelerate our growth story."

The acquisition will strengthen Siegfried's position in the United States, the world's largest pharmaceutical market, and enables Siegfried to provide comprehensive support to customers in the pre-clinical and clinical development and manufacturing of Drug Substances. This further expands Siegfried's offering, particularly for small and medium-sized pharmaceutical companies. The focus on early-phase CDMO services will further strengthen Siegfried's Drug Substance pipeline by capturing additional attractive opportunities in their early stage, creating significant growth opportunities in the future.

The acquisition is financed from existing funds. The outlook for 2024 and the mid-term financial targets remain unchanged.

Analyst Call

Siegfried will host an analyst call on June 12 at 10:00 am CEST. To participate in the analyst call, please follow the dial-in information below.

[Click here to join the meeting](#)

Meeting ID: 359 199 908 234

Passcode: ICWXMQ

About Siegfried







The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on the SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.

Cautionary Statements Regarding Forward-Looking Statements

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.

Download the media release and presentation

| | |
|--------------------------------|---|
| Media release |   |
| Medienmitteilung (DE) |   |
| Analyst Call presentation (EN) |   |

Subscribe to our news alerts

Sign up to stay up to date on Siegfried and our business performance.

E-Mail* **Subscribe**

We keep your data private and only share it with third parties that make this service possible. [Read our privacy policy](#) for more information.

Contact

Let's get in touch





Peter Stierli
Head Corporate Communications

☎ +41 62 746 15 51

✉ Get in touch



Reto Suter
Chief Financial Officer

 +41 62 746 11 35
 Get in touch

[to top](#) ↑

expect more

Siegfried AG

Untere Brühlstrasse 4
4800 Zofingen, Switzerland

 +41 62 746 11 11

About us

[Our company](#)

[Sustainability](#)

[Media](#)

[Investors](#)

[Careers](#)

Helpful resources

[Expert insights](#)

[News archive](#)

[Reports](#)

[Terms and conditions](#)

Offering

[Drug Substances](#)

[Drug Products](#)

[Technologies](#)



[Privacy Policy](#)

[Legal disclaimer](#)

[Imprint](#)

2024 © Siegfried Holding AG